The FDA approves the use of Novo Nordisk’s (NVO +1.6%) Fiasp (insulin aspart injection) 100 u/mL in insulin infusion pumps for patients with type 1 or type 2 diabetes.
https://seekingalpha.com/news/3507778-fda-oks-expanded-use-novos-fiasp-insulin-shares-2-percent
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.